Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Primary analysis of SAKK 06/17: perioperative chemoimmunotherapy with durvalumab for operable MIUC

Richard Cathomas, MD, PhD, Hospital Graubünden, Chur, Switzerland, shares the primary analysis of the open-label, single-arm Phase II SAKK 06/17 (NCT03406650) trial exploring the addition of neoadjuvant and adjuvant immunotherapy (IO) with the anti-PD-L1 antibody durvalumab, to standard neoadjuvant chemotherapy (with cisplatin/gemcitabine) and surgery in urothelial carcinoma. The primary endpoint was event-free survival (EFS) at 2 years after neoadjuvant trial treatment start. Secondary endpoints included pathologic response, recurrence-free survival after R0 resection (RFS), overall-survival (OS) and safety. 61 patients were included in the trial. Pathologic response was achieved in 32 patients. EFS at 2 years was 76.1%, RFS at 2 years following R0 resection was 83.5% and OS at years was 87.3%. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.